SCHEMBL14680406

SCHEMBL14680406

CC(C)(C)OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@@H](N)CCC(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 6/20 0.39
▸ ATM Q13315 2/20 0.38
▸ GNAI3 P08754 1/20 0.38
▸ GNAO1 P09471 1/20 0.38
▸ GNAI1 P63096 1/20 0.38
▸ NOD1 Q9Y239 1/20 0.38
▸ NPSR1 Q6W5P4 5/20 0.37
▸ KMT2A Q03164 4/20 0.37
▸ POLB P06746 3/20 0.37
▸ MEN1 O00255 3/20 0.37
▸ DPP7 Q9UHL4 2/20 0.36
▸ PLK1 P53350 1/20 0.36
▸ MAPT P10636 3/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ RRM1 P23921 1/20 0.34
▸ FOLH1 Q04609 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CPB1 P15086 1/20 0.34
▸ CPB2 Q96IY4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29679547 0.87 TDP1 (0.40) TDP1ATMGNAI3GNAO1GNAI1
SCHEMBL29679271 0.87 FOLH1 (0.47) TDP1ATMGNAI3GNAO1GNAI1
SCHEMBL14680632 0.86 FNTA (0.41) TDP1ATMPOLBPLK1MAPT
SCHEMBL29679190 0.86 TDP1 (0.39) TDP1ATMGNAI3GNAO1GNAI1
SCHEMBL19756833 0.85 FOLH1 (0.43) TDP1ATMNPSR1KMT2APOLB
SCHEMBL14680455 0.85 FOLH1 (0.43) TDP1ATMNPSR1KMT2APOLB
SCHEMBL19079056 0.84 TDP1 (0.44) TDP1NPSR1KMT2AMEN1MAPT
SCHEMBL19754085 0.82 FOLH1 (0.40) TDP1ATMNPSR1KMT2APOLB
SCHEMBL18407100 0.81 CAPN1 (0.38) TDP1ATMNPSR1KMT2APOLB
SCHEMBL10089717 0.80 FOLH1 (0.43) TDP1ATMKMT2APOLBFOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9388144-B2 Radiolabeled prostate specific membrane antigen inhibitors MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2016-07-12 — — US disclosed
US-20150078998-A1 RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS MOLECULAR INSIGHT PHARMACEUTICALS (US) 2015-03-19 — — US disclosed
US-8926944-B2 Radiolabeled prostate specific membrane antigen inhibitors MOLECULAR INSIGHT PHARMACEUTICALS (US) 2015-01-06 — — US disclosed
US-20130034494-A1 RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS MOLECULAR INSIGHT PHARMACEUTICALS 2013-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130034494-A1 RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS KLK3, FOLH1, PSMA1 TDP1 3701/4885ATM 2802/4885GNAI3 607/4885
US-20150078998-A1 RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS KLK3, FOLH1, PSMA2 TDP1 3742/4885ATM 2814/4885GNAI3 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback